Total Payments
$47,768
2021 Payments
$1,053
Companies
52
Transactions
633
Medicare Patients
2,210
Medicare Billing
$366,297
Payment Breakdown by Category
Other$37,625 (78.8%)
Food & Beverage$9,336 (19.5%)
Travel$615.37 (1.3%)
Education$191.49 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,625 | 21 | 78.8% |
| Food and Beverage | $9,336 | 566 | 19.5% |
| Travel and Lodging | $615.37 | 2 | 1.3% |
| Education | $191.49 | 44 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Assertio Therapeutics, Inc. | $17,562 | 36 | $0 (2020) |
| Collegium Pharmaceutical, Inc. | $16,888 | 143 | $0 (2021) |
| Depomed, Inc. | $6,966 | 12 | $0 (2017) |
| Daiichi Sankyo Inc. | $1,147 | 86 | $0 (2019) |
| Allergan, Inc. | $495.94 | 35 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $384.58 | 32 | $0 (2021) |
| Biohaven Pharmaceuticals, Inc. | $383.56 | 13 | $0 (2021) |
| SCILEX PHARMACEUTICALS INC. | $278.97 | 25 | $0 (2020) |
| Pernix Therapeutics Holdings, Inc. | $258.48 | 29 | $0 (2018) |
| Nevro Corp. | $239.78 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $1,053 | 50 | Biohaven Pharmaceuticals, Inc. ($363.99) |
| 2020 | $1,010 | 85 | Collegium Pharmaceutical, Inc. ($174.18) |
| 2019 | $1,612 | 126 | Collegium Pharmaceutical, Inc. ($246.88) |
| 2018 | $21,514 | 192 | Assertio Therapeutics, Inc. ($17,407) |
| 2017 | $22,579 | 180 | Collegium Pharmaceutical, Inc. ($13,947) |
All Payment Transactions
633 individual payment records from CMS Open Payments — Page 26 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/25/2017 | Purdue Pharma L.P. | OXYCONTIN (Drug), BUTRANS, HYSINGLA ER | Food and Beverage | Cash or cash equivalent | $13.56 | General |
| Category: PAIN MANAGEMENT | ||||||
| 01/25/2017 | Collegium Pharmaceutical, Inc. | Xtampza ER (Drug) | Food and Beverage | Cash or cash equivalent | $6.20 | General |
| Category: Opioid Analgesic | ||||||
| 01/24/2017 | PFIZER INC. | FLECTOR PATCH (Drug), LYRICA, EMBEDA | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 01/18/2017 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Opioid Induced Constipation | ||||||
| 01/18/2017 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $0.86 | General |
| Category: Opioid Induced Constipation | ||||||
| 01/17/2017 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $6.06 | General |
| Category: Opioid Induced Constipation | ||||||
| 01/13/2017 | Daiichi Sankyo Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $1.67 | General |
| Category: Opioid Induced Constipation | ||||||
| 01/02/2017 | Teva Pharmaceuticals USA, Inc. | AMRIX (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Central Nervous System | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 10 | 658 | 1,212 | $286,350 | $89,886 |
| 2020 | 17 | 1,552 | 3,676 | $939,883 | $276,411 |
Total Patients
2,210
Total Services
4,888
Medicare Billing
$366,297
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 97 | 140 | $182,000 | $34,075 | 18.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 145 | 288 | $40,589 | $26,347 | 64.9% |
| 62323 | Injection of substance into spinal canal of lower back or sacrum using imaging guidance | Office | 2021 | 26 | 47 | $23,500 | $11,495 | 48.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 69 | 109 | $9,809 | $6,575 | 67.0% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 191 | 418 | $10,450 | $5,250 | 50.2% |
| 20552 | Injections of trigger points in 1 or 2 muscles | Office | 2021 | 29 | 49 | $3,408 | $2,167 | 63.6% |
| 76942 | Ultrasonic guidance imaging supervision and interpretation for insertion of needle | Office | 2021 | 26 | 44 | $3,019 | $2,048 | 67.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $2,173 | $1,444 | 66.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 36 | 58 | $6,554 | $481.48 | 7.3% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2021 | 28 | 48 | $4,848 | $4.32 | 0.1% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 278 | 495 | $643,500 | $121,149 | 18.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 380 | 1,319 | $121,037 | $82,821 | 68.4% |
| 62323 | Injection of substance into spinal canal of lower back or sacrum using imaging guidance | Office | 2020 | 57 | 99 | $49,500 | $23,872 | 48.2% |
| 80305 | Testing for presence of drug | Office | 2020 | 368 | 1,052 | $26,300 | $13,161 | 50.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 46 | 46 | $9,168 | $6,855 | 74.8% |
| 20552 | Injections of trigger points in 1 or 2 muscles | Office | 2020 | 68 | 117 | $8,543 | $5,587 | 65.4% |
| 76942 | Ultrasonic guidance imaging supervision and interpretation for insertion of needle | Office | 2020 | 64 | 106 | $8,115 | $5,210 | 64.2% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 23 | 23 | $26,450 | $4,539 | 17.2% |
| 20611 | Aspiration and/or injection of major joint or joint capsule with recording and reporting using ultrasound guidance | Office | 2020 | 24 | 41 | $6,150 | $3,668 | 59.6% |
| 64493 | Injections of lower or sacral spine facet joint using imaging guidance | Office | 2020 | 14 | 22 | $4,653 | $3,446 | 74.1% |
| 64494 | Injections of lower or sacral spine facet joint using imaging guidance | Office | 2020 | 14 | 22 | $2,373 | $1,880 | 79.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2020 | 87 | 151 | $17,063 | $1,386 | 8.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 16 | 19 | $1,520 | $1,209 | 79.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 25 | 26 | $1,583 | $1,056 | 66.7% |
| 86328 | Ia nfct ab sarscov2 covid19 | Office | 2020 | 11 | 11 | $1,100 | $497.53 | 45.2% |
About Dr. Phillip Fyman, MD
Dr. Phillip Fyman, MD is a Interventional Pain Medicine healthcare provider based in Syosset, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528050051.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Phillip Fyman, MD has received a total of $47,768 in payments from pharmaceutical and medical device companies, with $1,053 received in 2021. These payments were reported across 633 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($37,625).
As a Medicare-enrolled provider, Fyman has provided services to 2,210 Medicare beneficiaries, totaling 4,888 services with total Medicare billing of $366,297. Data is available for 2 years (2020–2021), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Pain Medicine
- Location Syosset, NY
- Active Since 08/19/2005
- Last Updated 12/14/2009
- Taxonomy Code 208VP0014X
- Entity Type Individual
- NPI Number 1528050051
Products in Payments
- Gralise (Drug) $24,321
- Xtampza ER (Drug) $16,159
- Morphabond ER (Drug) $735.46
- XTAMPZA (Drug) $561.41
- Movantik (Drug) $443.64
- NURTEC ODT (Drug) $383.56
- ZOHYDRO ER (Drug) $258.48
- BOTOX (Biological) $229.34
- RELISTOR (Drug) $207.50
- MOVANTIK (Drug) $189.88
- Horizant (Drug) $189.49
- Senza Spinal Cord Stimulation System (Device) $173.78
- Zipsor (Drug) $160.93
- Dayvigo (Drug) $153.91
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $151.55
- RELISTOR ORAL (Drug) $149.25
- UBRELVY (Drug) $143.83
- Evzio (Drug) $131.73
- ZTLido (Drug) $127.42
- BELBUCA (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.